Lla, Rambaldi (uniMi): “The objective today is healing”

“Speaking of the main objective of therapeutic treatments for acute lymphoblastic leukemia we can say that today it is recovery. It is amazing to be able to affirm this even in adult patients currently enrolled in research protocols.” Thus Alessandro Rambaldi, professor of Hematology at the University of Milan, on the sidelines of the event with which Amgen illustrated the results of the Phase III E1910 clinical study which demonstrate how the introduction of the bispecific monoclonal antibody blinatumomab in the first line of treatment significantly increases the overall survival of patients with newly diagnosed Ph- B lymphocyte acute lymphoblastic leukemia (ALL).